演題

Trends in the outcomes of breast cancer according to the subtypes

[演者] 徳永 えり子:1
[著者] 山下 奈真:2, 田中 仁寛:2, 井上 有香:2, 安藤 幸滋:2, 中島 雄一郎:2, 大垣 吉平:2, 佐伯 浩司:2, 沖 英次:2, 前原 喜彦:2
1:九州大学九州連携臨床腫瘍学, 2:九州大学消化器・総合外科

Purpose: The improvements in early detection and treatment have improved the outcome of breast cancer. The aim of this study is to investigate the relationships between the trends in the outcomes and the subtypes of breast cancer. Patients and methods: A total of 676 women with stage I-III primary breast cancer were included in this study, who underwent surgery between 1994 and 2011 without neoadjuvant systemic therapy. They were divided into two time cohorts depending on whether the date of surgery was before or after 2003. Cohort A (1994-2002) and B (2003-2011) included 232 and 444 patients, respectively. Clinicopathological characteristics, treatments, and outcomes were compared.Results:There were significantly more T1, ER-positive, PR-positive, lower nuclear grade, node-negative cases in cohort B. The rate of the adjuvant endocrine therapy and chemotherapy was significantly higher in cohort B. The prognosis was significantly better in cohort B. When patients were categorized into 4 subgroups by the expression of hormone receptor (HR) and HER-2 status, improvement of the prognosis in cohort B was especially significant in HR+/HER2- and HR-/HER2+ subgroups. However, the prognosis of the HR-/HER2- (triple negative; TN) subgroup was not different between cohort A and B, regardless of the significantly higher rate of the adjuvant chemotherapy in cohort B.Conclusions:The outcome of breast cancer was improved over time, especially in HR+/HER2- and HR-/HER2+ subgroups. It is important to develop different therapeutic strategies for TNBC.
詳細検索
アプリバナー iPhone版,iPad版 Android版